These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26494953)

  • 1. Companion diagnostics for the targeted therapy of gastric cancer.
    Yoo C; Park YS
    World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in gastric cancer: Where are we and where are we going?
    Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
    World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug sensitivity testing platforms for gastric cancer diagnostics.
    Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
    J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targeting to treat gastric cancer.
    Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
    World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
    Yashiro M; Matsuoka T
    World J Gastroenterol; 2016 Feb; 22(8):2415-23. PubMed ID: 26937130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing strategies for target therapy in gastric cancer.
    Lee SY; Oh SC
    World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging therapies in unresectable and recurrent gastric cancer.
    Jou E; Rajdev L
    World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
    Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
    World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of advanced gastric cancer: the role of new molecular drugs.
    De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M
    World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic and metabolic prediction of response to therapy in gastric cancer.
    Aichler M; Luber B; Lordick F; Walch A
    World J Gastroenterol; 2014 Oct; 20(38):13648-57. PubMed ID: 25320503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular aspects of breast cancer: Targets and therapies.
    Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
    Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
    Chen DH; Yu JW; Jiang BJ
    World J Gastroenterol; 2015 Sep; 21(33):9707-16. PubMed ID: 26361417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in gastric cancer and future perspectives.
    Yazici O; Sendur MA; Ozdemir N; Aksoy S
    World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.